Last reviewed · How we verify

NCT06816524

The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency

Not yet recruiting NA Last updated 26 December 2025
What this trial tests

NA trial testing Iron syrup in Iron Deficiencies in 324 participants. Not yet recruiting.

Timeline
5 January 2026
Primary endpoint
31 December 2027
30 April 2028

Quick facts

Lead sponsorNicole Stoffel
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposeother
Enrollment324
Start date5 January 2026
Primary completion31 December 2027
Estimated completion30 April 2028

Drugs / interventions tested

Conditions studied

Sponsor

Nicole Stoffel — full company profile →

Who can join

Adults 6 Months to 6 Months, any sex, with Iron Deficiencies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination. In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Iron syrup

Trials testing the same drug.

Other recruiting trials for Iron Deficiencies

Currently open trials in the same condition.

Other Nicole Stoffel trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06816524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing